PNC Financial Services Group’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-306
| Closed | -$6.59K | – | 5170 |
|
|
2025
Q4 | $6.59K | Buy |
306
+105
| +52% | +$2.04K | ﹤0.01% | 4124 |
|
|
2025
Q3 | $3.07K | Buy |
+201
| New | +$2.62K | ﹤0.01% | 4380 |
|
|
2024
Q4 | – | Sell |
-115
| Closed | -$1.51K | – | 4789 |
|
|
2024
Q3 | $1.51K | Hold |
115
| – | – | ﹤0.01% | 4349 |
|
|
2024
Q2 | $1.62K | Sell |
115
-52
| -31% | -$848 | ﹤0.01% | 4311 |
|
|
2024
Q1 | $2.82K | Buy |
+167
| New | +$2.49K | ﹤0.01% | 4123 |
|
|
2022
Q3 | – | Sell |
-500
| Closed | -$1K | – | 4442 |
|
|
2022
Q2 | $1K | Hold |
500
| – | – | ﹤0.01% | 4313 |
|
|
2022
Q1 | $3K | Hold |
500
| – | – | ﹤0.01% | 4094 |
|
|
2021
Q4 | $4K | Hold |
500
| – | – | ﹤0.01% | 4002 |
|
|
2021
Q3 | $5K | Hold |
500
| – | – | ﹤0.01% | 3925 |
|
|
2021
Q2 | $3K | Buy |
+500
| New | +$3.97K | ﹤0.01% | 3970 |
|
|
2020
Q3 | – | Sell |
-300
| Closed | -$2K | – | 3919 |
|
|
2020
Q2 | $2K | Buy |
+300
| New | +$2.65K | ﹤0.01% | 3750 |
|
|
2017
Q3 | – | Sell |
-10,956
| Closed | -$121K | – | 4134 |
|
|
2017
Q2 | $121K | Buy |
10,956
+10,532
| +2,484% | +$106K | ﹤0.01% | 2411 |
|
|
2017
Q1 | $4K | Hold |
424
| – | – | ﹤0.01% | 3783 |
|
|
2016
Q4 | $4K | Sell |
424
-496,443
| -100% | -$5.46M | ﹤0.01% | 3704 |
|
|
2016
Q3 | $6.16M | Buy |
496,867
+36,657
| +8% | +$479K | 0.01% | 604 |
|
|
2016
Q2 | $4.94M | Buy |
460,210
+87,954
| +24% | +$938K | 0.01% | 646 |
|
|
2016
Q1 | $4.11M | Buy |
+372,256
| New | +$3.7M | ﹤0.01% | 684 |
|
|
2015
Q3 | – | Sell |
-147
| Closed | -$3K | – | 4611 |
|
|
2015
Q2 | $3K | Buy |
+147
| New | +$2.64K | ﹤0.01% | 4244 |
|
|
2014
Q2 | – | Sell |
-15,000
| Closed | -$201K | – | 3810 |
|
|
2014
Q1 | $201K | Buy |
15,000
+970
| +7% | +$10.4K | ﹤0.01% | 1893 |
|
|
2013
Q4 | $113K | Buy |
14,030
+6,000
| +75% | +$42.3K | ﹤0.01% | 2121 |
|
|
2013
Q3 | $53K | Buy |
+8,030
| New | +$49.4K | ﹤0.01% | 2455 |
|
Other funds holding AVDL
PNC Financial Services Group's AVDL Position: Q1 2026 in Review
PNC Financial Services Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 306 shares — an estimated $6.59K sold.
PNC Financial Services Group first reported a position in AVDL in Q3 2013 and held it in 21 quarters. The position peaked at $6.16M in Q3 2016. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- PNC Financial Services Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- PNC Financial Services Group sold 306 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.59K.
- PNC Financial Services Group first reported a position in Avadel Pharmaceuticals in Q3 2013 and held it in 21 quarters.
- PNC Financial Services Group's Avadel Pharmaceuticals position peaked at $6.16M in Q3 2016.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.